Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia

European Journal of Clinical Pharmacology

Volumn 68, Issue 9, 2012, Pages 1233-1242

  De Beaumais, Tiphaine Adam ^a   Jacqz Aigrain, Evelyne ^a,b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

6 mercaptopurine; Acute lymphoblastic leukemia; Pediatrics; Pharmacogenetics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; XANTHINE OXIDASE;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE GENE; ACUTE LYMPHOCYTIC LEUKEMIA; CANCER SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; EVENT FREE SURVIVAL; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LOCATION; GENETIC VARIABILITY; GUANOSINE MONOPHOSPHATE SYNTHASE GENE; HUMAN; HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; INOSINE MONOPHOSPHATE DEHYDROGENASE 1 GENE; INOSINE MONOPHOSPHATE DEHYDROGENASE 2 GENE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE GENE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; THIOPURINE S METHYLTRANSFERASE GENE; XANTHINE OXIDASE GENE;

6-MERCAPTOPURINE; AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOTRANSFORMATION; CHILD; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84866631524     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1251-4     Document Type: Review

References (69)

1. Schmiegelow K, Schrøder H, Gustafsson G et al (1995) Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. J Clin Oncol 13(2):345-351
2. Elion GB, Hitchings GH, Vanderwerff H (1951) Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 192(2):505-518
3. Adam de Beaumais T, Fakhoury M, Medard Y et al (2011) Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 71(4):575-584
4. McLeod HL, Krynetski EY, Relling MV, Evans WE (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4):567-572
5. Fakhoury M, de Beaumais T, Médard Y, Jacqz-Aigrain E (2010) Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits. Therapie 65(3):187-193
6. Bostrom B, Erdmann G (1993) Cellular pharmacology of 6- mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 15(1):80-86
7. Swann PF, Waters TR, Moulton DC et al (1996) Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273(5278):1109-1111
8. Dervieux T, Blanco JG, Krynetski EY, Vanin EF, Roussel MF, Relling MV (2001) Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res 61(15):5810-5816
9. Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8(1):24-36
10. Relling MV, Gardner EE, Sandborn WJ et al (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 89(3):387-391
11. McLeod HL, Lin JS, Scott EP, Pui CH, Evans WE (1994) Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 55(1):15-20
12. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 119(6):985-989
13. Lennard L, Van Loon JA, Lilleyman JS,Weinshilboum RM (1987) Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 41(1):18-25
14. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM (1990) Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336(8709):225-229
15. Loennechen T, Utsi E, Hartz I, Lysaa R, Kildalsen H, Aarbakke J (2001) Detection of one single mutation predicts thiopurine Smethyltransferase activity in a population of Saami in northern Norway. Clin Pharmacol Ther 70(2):183-188
16. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al (1998) Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125(4):879-887
17. Tinel M, Berson A, Pessayre D et al (1991) Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol 32(6):729-734
18. De Beaumais TA, Fakhoury M, Pigneur B et al (2009) Characterization of a novel TPMT mutation associated with azathioprineinduced myelosuppression. Br J Clin Pharmacol 68(5):770-772
19. Szumlanski C, Otterness D, Her C et al (1996) Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 15(1):17-30
20. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N (2006) Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 52 (2):240-247
21. von Ahsen N, Oellerich M, Armstrong VW (2008) Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther Drug Monit 30(1):16-22
22. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A (2007) The ITPA c.94C>A and g.IVS2 + 21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta 1772(1):96-102
23. Sumi S, Marinaki AM, Arenas M et al (2002) Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 111(4-5):360-367
24. Allorge D, Hamdan R, Broly F, Libersa C, Colombel J-F (2005) ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54(4):565
25. Stocco G, Cheok MH, Crews KR et al (2009) Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 85(2):164-172
26. Tai HL, Fessing MY, Bonten EJ et al (1999) Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT
27. Pharmacogenetics 9(5):641-650
28. Milek M, Karas Kuzelicki N, Smid A, Mlinaric-Rascan I (2009) Sadenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts. Biochem Pharmacol 77(12):1845-1853
29. Martin YN, Salavaggione OE, Eckloff BW, Wieben ED, Schaid DJ, Weinshilboum RM (2006) Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenet Genomics 16(4):265-277
30. Arenas M, Simpson G, Lewis CM et al (2005) Genetic variation in the MTHFR gene influences thiopurine methyltransferase activity. Clin Chem 51(12):2371-2374
31. Guerciolini R, Szumlanski C, Weinshilboum RM (1991) Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 50(6):663-672
32. Minoshima S, Wang Y, Ichida K, Nishino T, Shimizu N (1995) Mapping of the gene for human xanthine dehydrogenase (oxidase) (XDH) to band p23 of chromosome 2. Cytogenet Cell Genet 68(1-2):52-53
33. Wong DR, Derijks LJJ, den DulkMO, Gemmeke EHKM, Hooymans PM (2007) The role of xanthine oxidase in thiopurine metabolism: a case report. Ther Drug Monit 29(6):845-848
34. Morgan E, Honig G, Nelson DJ (1981) Acute lymphocytic leukemia in a child with congenital xanthine oxidase deficiency: implications for therapy. Am J Pediatr Hematol Oncol 3(4):439-441
35. Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, O'Neill JP (2000) The spectrum of inherited mutations causing HPRT deficiency: 75 new cases and a review of 196 previously reported cases. Mutat Res 463(3):309-326
36. Kudo M, Saito Y, Sasaki T et al (2009) Genetic variations in the HGPRT, ITPA, IMPDH1, IMPDH2, and GMPS genes in Japanese individuals. Drug Metab Pharmacokinet 24(6):557-564
37. Ding L, Zhang F-B, Liu H et al (2011) Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 18 (1):63-73.
38. Pieters R, Huismans DR, Loonen AH et al (1992) Hypoxanthineguanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer 51(2):213-217
39. Haglund S, Taipalensuu J, Peterson C, Almer S (2008) IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 65(1):69-77
40. Jain J, Almquist SJ, Ford PJ et al (2004) Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 67(4):767-776
41. Bowne SJ, Liu Q, Sullivan LS et al (2006) Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration? Invest Ophthalmol Vis Sci 47(9):3754-3765
42. Zaza G, Cheok M, Krynetskaia N et al (2010) Thiopurine pathway. Pharmacogenet Genomics 20(9):573-574
43. Wielinga PR, Reid G, Challa EE et al (2002) Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62(6):1321-1331
44. Reid G, Wielinga P, Zelcer N et al (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63(5): 1094-1103
45. Adachi M, Reid G, Schuetz JD (2002) Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev 54(10):1333-1342
46. Leeder JS, Kearns GL, Spielberg SP, van den Anker J (2010) Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 50(12):1377-1387
47. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology-drugdisposition, action, and therapy in infants and children. N Engl J Med 349(12):1157-1167
48. Ganiere-Monteil C, Medard Y, Lejus C et al (2004) Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 60 (2):89-96
49. McLeod HL, Krynetski EY, Wilimas JA, Evans WE (1995) Higher activity of polymorphic thiopurine S-methyltransferase in erythrocytes from neonates compared to adults. Pharmacogenetics 5 (5):281-286
50. CIGNA Health Insurance. CIGNA Health Insurance Company: Dental, Medical, Life & Disability Benefits and Coverage http:// www.cigna.com/customer-care/ healthcare-professional/coverage- positions/medical/mm-0016- coveragepositioncriteria-monitoring- thiopurine-levels-in-ibd.pdf
51. Relling MV, Hancock ML, Rivera GK et al (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine Smethyltransferase gene locus. J Natl Cancer Inst 91(23):2001-2008
52. Hedeland RL, Hvidt K, Nersting J et al (2010) DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 66(3):485-491
53. Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I (2009) 5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res 33(10):1344-1348
54. Dorababu P, Nagesh N, Linga VG et al (2011) Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6- mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol. doi:10.1007/s00228-011- 1133-1
55. Schmidt LE, Dalhoff K (2002) Food-drug interactions. Drugs 62 (10):1481-1502
56. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE (1997) Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT
57. Nguyen CM, Mendes MAS, Ma JD (2011) Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr 3:RRN1236
58. Wan RosalinaWR, Teh LK, Mohamad N et al (2011) Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther. Available from: doi:10.1111/j.1365-2710.2011.01272.x
59. Hawwa AF,Millership JS, Collier PS et al (2008) Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 66(4):517-528
60. Kudo M, Moteki T, Sasaki T et al (2008) Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet Genomics 18(3):243-251
61. Kang SS, Wong PW, Bock HG, Horwitz A, Grix A (1991) Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations. Am J Hum Genet 48(3):546-551
62. Karas-Kuzelicki N, Jazbec J, Milek M, Mlinaric-Rascan I (2009) Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 23(5):971-974
63. van der Put NM, Gabreëls F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62(5):1044-1051
64. Ogino S, Wilson RB (2003) Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum Genet 48(1):1-7
65. Roberts RL, Gearry RB, Barclay ML, Kennedy MA (2007) IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance. Pharmacogenomics J 7(5):312-317
66. Wang J, Zeevi A, Webber S et al (2007) A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 17(4):283-290
67. Grinyó J, Vanrenterghem Y, Nashan B et al (2008) Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21(9):879-891
68. Janke D, Mehralivand S, Strand D et al (2008) 6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum Mutat 29(5):659-669
69. Ban H, Andoh A, Imaeda H et al (2010) The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 45(10):1014-1021